We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.19 | 0.75% | 25.45 | 25.54 | 25.20 | 25.33 | 46,479,621 | 00:58:17 |
From Apr 2019 to Apr 2024
By Tess Stynes
Pfizer Inc. (PFE) said its experimental anti-cholesterol treatment significantly reduced LDL-C cholesterol across several dosing levels in a Phase 2b study of patients at high risk for cardiovascular events.
Bococizumab--also known as RN316--is part of a class of treatments called PCSK9 inhibitors, which are being developed by several major drug companies. Analysts and investors have watched development of the drugs closely because of their potential to treat millions of patients whose high cholesterol isn't well controlled with statins.
The study included statin-treated patients with high cholesterol who received doses of either bococizumab twice or once monthly subcutaneous administration or placebo. The study met its primary endpoint across all doses, Pfizer said.
Elevated LDL-C is recognized as a major risk factor for cardiovascular disease.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
